Fig. 1
From: A mouse model of vitiligo based on endogenous auto-reactive CD8 + T cell targeting skin melanocyte
Schema for vitiligo mouse model induction. a Schematic diagram of the induction procedure for vitiligo mouse model. b Experimental procedure to evaluate the depletion efficiency of anti-CD4 depletion antibody. Two doses of anti-mouse CD4 depletion antibody were injected intraperitoneally, at 10 μg/g body weight (~ 200 μg) per animal per day. (c-d) Representative FACS profiles and quantification of CD3 + CD4 + T cells in spleen c, and tail skin epidermis d, of mice that were either untreated (Ctl) or treated with anti-CD4 depletion antibody. Cells were pre-gated on CD45 + live singlets. e Representative FACS profiles and quantification of CD4 + Foxp3 + Tregs in skin draining lymph node with or without anti-CD4 depletion antibody treatment. Cells were pre-gated on CD45 + CD3 + live singlets. f Representative images to illustrate the color of cell pellets of B16F10 cells under different culture conditions. g Representative brightfield images in a petri dish and cell counts of B16F10 cells that will yield cell pellets with different colors. h The tumorigenesis capacity of B16F10 cells with different colors of pellets. The tumor size was measured at Day 12 post B16F10 inoculation. i Quantifications represent the percentage of vitiligo developed (determined by marked melanocyte loss and CD8 + T cell infiltration at Day 33) with different tumor size at Day 12 post B16F10 inoculation. n = 10 (0–0.02 cm3), 9 (0.02–0.05 cm3), 6 (0.05–0.1 cm3), 8 (0.1–0.15 cm3), 5 (0.15–0.2 cm3), and 6 (> 0.2 cm3). j Photographs of injection area at Day 0, 4, and 12 of B16F10 intradermal injection. A small bubble will appear underneath the skin after the injection procedure. The tumor size is 2–4 mm on Day 4 and 5–15 mm on Day 12 in diameter. k Representative images of dorsal hair coat on Day 60 and tail on Day 120 after the vitiligo induction